20920-98-3 Usage
Description
6-methoxy-3,4-dihydro-2H-chromen-2-one, commonly known as scopoletin, is a naturally occurring coumarin compound found in various plant species. It is recognized for its diverse pharmacological properties, such as anti-inflammatory, antioxidant, and anti-cancer effects. Scopoletin has been studied for its potential to inhibit tumor growth and induce cell death in cancer cells, making it a promising candidate for future cancer therapies. It also plays a role in cardiovascular health and offers protection against oxidative stress. Furthermore, scopoletin has been utilized in traditional medicine for its analgesic and anti-inflammatory properties, highlighting its significance in natural product research.
Uses
Used in Pharmaceutical Industry:
6-methoxy-3,4-dihydro-2H-chromen-2-one is used as a pharmacological agent for its anti-inflammatory properties, helping to reduce inflammation and alleviate pain in various conditions.
Used in Cancer Therapy:
In the field of oncology, 6-methoxy-3,4-dihydro-2H-chromen-2-one is used as a potential anti-cancer agent, exhibiting the ability to inhibit tumor growth and induce cell death in cancer cells, making it a promising candidate for future cancer treatments.
Used in Cardiovascular Health:
6-methoxy-3,4-dihydro-2H-chromen-2-one is used as a cardiovascular protective agent, contributing to the maintenance of cardiovascular health through its antioxidant properties and its ability to protect against oxidative stress.
Used in Traditional Medicine:
In traditional medicine, 6-methoxy-3,4-dihydro-2H-chromen-2-one is used as an analgesic and anti-inflammatory agent, providing relief from pain and reducing inflammation in various ailments.
Used in Antioxidant Formulations:
6-methoxy-3,4-dihydro-2H-chromen-2-one is used as an antioxidant in various formulations, including dietary supplements and skincare products, to protect cells from oxidative damage and promote overall health.
Check Digit Verification of cas no
The CAS Registry Mumber 20920-98-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 2,0,9,2 and 0 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 20920-98:
(7*2)+(6*0)+(5*9)+(4*2)+(3*0)+(2*9)+(1*8)=93
93 % 10 = 3
So 20920-98-3 is a valid CAS Registry Number.
20920-98-3Relevant articles and documents
Organocatalyst-Mediated Dynamic Kinetic Enantioselective Acylation of 2-Chromanols
Glazier, Daniel A.,Schroeder, John M.,Liu, Jitian,Tang, Weiping
, p. 4646 - 4649 (2018)
We recently developed a novel chiral catalyst-directed dynamic kinetic diastereoselective acylation of hemiacetals for the synthesis of carbohydrates. In this update, we describe a catalytic method for the dynamic kinetic enantioselective acylation of 2-c
Substd. 2 - (chromane-6-carbonoyloxysilane) and its use as medicine iminothiazole-
-
Paragraph 0191, (2016/10/27)
PROBLEM TO BE SOLVED: To provide: a compound usable for disorders such as arrhythmia, cardiac failure and cerebral apoplexy caused by disturbance of intracellular calcium homeostasis of sodium-calcium exchanger (NCX), especially sodium-calcium exchanger of subtype 1 (NCX1); production method of the compound; use thereof as a pharmaceutical; and a pharmaceutical composition including the compound.SOLUTION: There is disclosed a substituted 2-(chroman-6-yloxy)-thiazole compound expressed by general formula I.
Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals
-
Paragraph 0155-0156, (2013/03/26)
Substituted 2-(chroman-6-yloxy)-thiazoles and their use as pharmaceuticals The present invention relates to substituted 2-(chroman-6-yloxy)-thiazoles of the formula I, in which Ar, R2, R3 and R4 are as defined in the claims. The compounds of the formula I are inhibitors of the sodium-calcium exchanger (NCX), especially of the sodium-calcium exchanger of subtype 1 (NCX1), and are suitable for the treatment of diverse disorders in which intracellular calcium homeostasis is disturbed, such as arrhythmias, heart failure and stroke. The invention furthermore relates to processes for the preparation of the compounds of the formula I, their use as pharmaceuticals, and pharmaceutical compositions comprising them.
